us
users
under
unique
regulator
regulators
recommend
research
reintroduction
reports
really
rule
ruled
rung
risk
risks
to
told
the
they
there
therapies
that
than
three
though
things
this
thursday
tumbled
tuesday
taking
take
time
on
of
office
other
observed
oversee
or
pain
painkillers
panel
patients
putting
profits
problems
products
presented
people
peter
pfizer
possible
place
dr
drug
drugs
decide
developed
deaths
days
david
dollars
doubled
doesn't
doctors
disease
food
for
fourth-quarter
friday
from
fda
fda's
firm's
fewer
facing
factors
a
and
any
analysts
announcement
at
attack
administration
advisory
after
are
as
asked
aside
approval
approve
appear
alarm
also
alternative
already
available
according
american
agency
about
will
with
withdrawn
withdrew
whether
who
which
was
would
were
went
sale
sales
said
say
safety
stroke
stopped
stomach
still
stem
sold
such
suggested
surprise
shops
showed
should
shelves
shares
selling
september
set
senate
slide
since
similar
have
has
had
harmful
handling
high
he
heart
hearing
head
been
benefits
bells
because
bextra
brand
but
back
battles
based
boost
body
by
linked
likely
litigation
light
last
legal
least
give
given
giving
gets
graham
it
its
inhibitors
increased
including
injured
investigations
information
independent
if
is
verdict
vioxx
vioxx-related
voluntarily
evidence
easier
earnings
earlier
explained
european
-
called
calculations
cause
caused
caught
cautious
cardiovascular
case
cox-2
consider
company
companies
cover
cost
celebrex
claim
class
clear
changed
criticism
create
names
new
news
need
not
note
november
year
merck
merck's
meanwhile
medicines
make
makes
may
market
marketed
many
move
more
months
millions
mr
justify
30
$1.1bn
$1.4bn
Â£581m
10%
18
kim
knowing
56,000